Erica A. Power

Erica A. Power

Auto-generated profile, based on publicly available information

Erica A. Power

Department of Cancer Biology, Stritch School of Medicine, Loyola University Chicago , Maywood, Illinois

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EPErica A. Power
Erica A. Power
JFJenelys Fernandez-Torres
Jenelys Fernandez-Torres
LZLiang Zhang
Liang Zhang
RYRuiyi Yaun
Ruiyi Yaun
FLFabrice Lucien
Fabrice Lucien
DDDavid J Daniels
David J Daniels
Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain tumor. While there are a number of in vivo rodent models for evaluating tumor biology and response to therapy, these models require significant time and resources. Here, we established the chick-embryo chorioallantoic (CAM) assay as an affordable and time efficient xenograft model for testing a variety of treatment approaches for DIPG. We found that patient-derived DIPG tumors develop in the CAM and maintain the same genetic and epigenetic characteristics of native DIPG tumors. We monitored tumor response to pharmaco- and radiation therapy by 3-D ultrasound volumetric and vasculature analysis. In this study, we established and validated the CAM model as a potential intermediate xenograft model for DIPG and its use for testing novel treatment approaches that include pharmacotherapy or radiation.

3 July 2024 in Immunotherapy
Verified
Journal Article
Closed access
EPErica A Power
Erica A Power
EMElena Millesi
Elena Millesi
JRJulian Simon Rechberger
Julian Simon Rechberger
DDDavid J Daniels
David J Daniels

21 January 2024 in World Neurosurgery
Verified
Journal Article
Closed access
JRJulian Simon Rechberger
Julian Simon Rechberger
EMElena Millesi
Elena Millesi
EPErica A. Power
Erica A. Power
HWHuan Wang
Huan Wang
SMSamir Mardini
Samir Mardini
DDDavid J Daniels
David J Daniels

6 January 2025 in Neuro-Oncology Advances
Verified
Journal Article
Open access
NFNoah Forrest
Noah Forrest
VGVijeeth Guggilla
Vijeeth Guggilla
ABApril Bell
April Bell
SZSusan Zelisko
Susan Zelisko
EFEmma M Federico
Emma M Federico
TWTheresa L Walunas
Theresa L Walunas
Background: In 2021, the World Health Organization reclassified glioblastomas to include only gliomas with wild-type isocitrate dehydrogenase (IDHwt). Reclassification has created a challenge for retrospective identification of patients with GBM, as many were classified with outdated definitions. This study aims to address this challenge by using natural language processing (NLP) on electronic health record (EHR) data to identify patients with wild-type IDH glioma. Methods: We manually adjudicated a subset of 1499 pathology records for evidence of IDHwt glioma as well as the methylation status of the MGMT promoter. We then trained several regularized logistic regression models that identify the IDH mutation and MGMT promoter status using biomedical concepts identified in the text. These models were then validated at a second site. Kaplan–Meier curves stratifying patients by their MGMT promoter methylation status and other clinical variables were constructed for further cohort characterization. Results: The best-performing model for identifying IDHwt glioma displayed an F1 measure of 0.88. Comparing patients with methylated and unmethylated MGMT promoter showed significant differences in median overall survival times (P < 0.001). Finally, the best-performing IDHwt glioma identification model displayed an F1 measure of 0.962 when implemented at a secondary site. Discussion: Our results suggest that we can identify patients with IDHwt glioma in pathology notes in the EHR using NLP. Our models displayed excellent performance at a secondary healthcare institution, demonstrating that they can identify multi-site GBM cohorts. Furthermore, our characterization of the NM GBM cohort recapitulated known survival trends, demonstrating the utility of EHR data in studying GBM in clinical settings.